ROCHESTER, Minn. — Mayo Clinic is creating a library of genomic sequencing data on 100,000 consented Mayo Clinic participants to advance research and patient care.

“We believe that whole exome sequencing has the potential to reveal predispositions to health problems and enable earlier use of preventive measures throughout a person’s lifespan,” says Keith Stewart, M.B., Ch.B., Carlson and Nelson Endowed director, Mayo Clinic Center for Individualized Medicine.

Mayo is collaborating with Helix, a population genomics company. Helix’s clinical Exome+ sequencing is a technology that reads all 20,000 genes that code for proteins, plus hundreds of thousands of regions outside the protein-coding regions that are known to be informative, and thus have the most impact on an individual’s health. This comprehensive DNA test uses Next Generation Sequencing technology to screen the exome for genetic variants that can significantly increase the risk for disease.

Participants’ DNA will undergo Exome+ sequencing with results returned over time to the participant, as well as their Mayo Clinic provider. This will allow Mayo to evaluate the benefits of Exome+ sequencing and the short- and long-term impact on health-related outcomes, health care utilization and physician acceptance.

For the initial part of the study, known as Tapestry, participants will receive results of screening for three highly actionable hereditary conditions that often go unrecognized, including familial hypercholesterolemia (FH), hereditary breast and ovarian cancer (BRCA1 and BRCA2), and Lynch syndrome, a form of hereditary colorectal cancer.

“Many individuals affected by these conditions are not aware they are at risk, but genetic screening can lead to diagnoses for individuals and their families,” says Konstantinos Lazaridis, M.D., associate director, Mayo Clinic Center for Individualized Medicine and principal investigator of the Tapestry study.

“We agree that Exome+ sequencing has the potential to impact health-related outcomes for many individuals. We look forward to working with Mayo to accelerate the integration of genomics into standard patient care and drive novel genetic discovery,” says Marc Stapley, Helix CEO.

Disclosure: Mayo Clinic has a financial interest in Helix.

###

About Mayo Clinic Center for Individualized Medicine
The Center for Individualized Medicine discovers and integrates the latest in genomic, molecular and clinical sciences into personalized care for each Mayo Clinic patient.  Learn more about the Center for Individualized Medicine.

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news and An Inside Look at Mayo Clinic for more information about Mayo.

About Helix
Helix is a population genomics company with a mission to empower every person to improve their life through DNA. Helix is accelerating the integration of genomic data into clinical care and broadening the impact of large-scale population health programs by providing comprehensive expertise in DNA sequencing, bioinformatics and individual engagement. Powered by their proprietary Exome+™ assay — a panel-grade clinical exome enhanced by more than 300,000 informative non-coding regions — Helix partners with health systems to provide a scalable solution which enables the discovery of medically relevant, potentially life-saving, genetic information. Additionally, Helix offers a suite of DNA-powered products for continued individual engagement and discovery. Helix is headquartered in the San Francisco Bay Area and has one of the world’s largest CLIA-certified, CAP-accredited Next Generation Sequencing labs, located in San Diego, California. Learn more at www.helix.com. Helix, the Helix logo, and Exome+ are trademarks of Helix Opco, LLC.

Media contacts:

• Colette Gallagher, Mayo Clinic Public Affairs, 507-284-5005, newsbureau@mayo.edu
• Helix, 415-692-6799, press@helix.com

The post Mayo Clinic to sequence 100K participants to build genomic database for improved care and research in collaboration with Helix appeared first on Mayo Clinic News Network.

More than 60 years ago, Alice Kalin was told the cancer in her leg would end her life. But a trip to Mayo Clinic and some advice from her surgeon would change everything.

Alice Kalin stood in the shower, tears streaming down her face. She'd been to the doctor, and the news was not good. There was a large tumor in her leg, and nothing could be done. "I was told to get my affairs in order," Alice tells us. "They said I had about a year left." She thought of her husband, of her five little children. And all she could do was cry.

Then she heard her husband's voice. "Get out of the shower," he told Alice, "there's someone here to see you." One of her husband's Air Force colleagues had come to the house. He was a new physician on the base and had trained at Mayo Clinic. He told Alice about one of his mentors, an orthopedic surgeon named William Bickel, M.D. "I think he can save your life," the young man told Alice. "My husband got emergency leave and we headed to Rochester," she says. They met with Dr. Bickel, and the rest — some 61 years later — is history. Joyful, wonderful, treasured history, some of which Alice, now 96, shared with us during a recent "pilgrimage" back to Rochester.

Read the rest of the story.

________________________________________________

This story originally appeared on the In the Loop blog.

The post In the Loop: She was told she had a year to live, 61 years ago appeared first on Mayo Clinic News Network.

Researchers, physicians and staff with the Advanced Diagnostics Laboratory, a joint collaboration between the Mayo Clinic Department of Laboratory Medicine and Pathology and the Center for Individualized Medicine, will take part in a community celebration of One Discovery Square on Sept. 19 from 4-6 p.m.

The grand opening event, held in conjunction with the Destination Medical Center’s annual meeting, is open to the public and features interactive displays, tenant activity booths, music, food, games and self-guided tours. The 90,000-square-foot, four-story bioscience building is located at 201-299 4th Street SW in the heart of downtown Rochester.

“By putting some of the world’s top medical researchers and state-of-the-art laboratories under one roof, we now have an extraordinary opportunity to accelerate discoveries of life-saving therapies and test development in individualized medicine for patients with complex diseases, including cancers,” says Keith Stewart, M.B., Ch.B., Carlson and Nelson Endowed Director of Mayo Clinic Center for Individualized Medicine.

Dr. Stewart says the Advanced Diagnostic Laboratory will initially support 14 projects in areas of disruptive technology, such as multi-omics, artificial intelligence and digital pathology, bringing together current and new testing platforms with multidisciplinary staff.

“The collaboration represents a new era in transforming human health through individualized medicine,” says Dr. Stewart. “Researchers will be encouraged to innovate with a goal of accelerating the development and launch of new products and services.”

In addition, the Advanced Diagnostic Laboratory will collaborate with companies, both inside and outside of One Discovery Square, to increase laboratory testing capabilities at Mayo Clinic and to provide alternate revenue sources through business partnerships.

One Discovery Square will also be home to two other Mayo Clinic departments: Biomedical Technology and Advanced Manufacturing of Regenerative Products. The building is part of a planned 16-block sub-district designed to be a hub for science and research.

Stay informed

Want to read more stories like this one?

Register to get weekly updates about new stories on Mayo Clinic Center for Individualized Medicine blog.

Join the conversation

For more information on the Mayo Clinic Center for Individualized Medicine, visit our blog, Facebook, LinkedIn or Twitter at @MayoClinicCIM

The post One Discovery Square provides a hub for innovation, state-of-the-art labs, top researchers appeared first on Mayo Clinic News Network.

For the past 30 years, I’ve been fortunate enough to work with and help many patients. But over that time, I’ve also met people who did not respond to therapy or had significant side effects, while others had marvelous responses. Cases like these show a clear need for personalized medicine. Fortunately, I’ve also seen the adoption of a new technology that allows us to gain unprecedented insight into a patient’s specific needs: DNA sequencing.

Everyone has their own unique sequence of DNA — a molecular fingerprint — that determines personal characteristics like height, hair and eye color, and risk for disease. Research has shown us that insights into a person’s DNA sequence allows us to personalize their health care to their own genetic makeup to better meet their needs.*

In the past decade, we’ve seen exponential growth in DNA sequencing technology and an expansion of its use in medicine.* In 2012, Mayo Clinic adopted DNA sequencing as a major tool in individualized medicine by using targeted gene panels and whole exome sequencing. We started by looking for actionable targets in patients with advanced cancers (unique features of a tumor that can make one therapeutic drug particularly effective). We quickly expanded this approach beyond cancer by opening clinics that helped to diagnose rare and undiagnosed diseases.

Rare and undiagnosed diseases

Our patients come from around the world, often seeking a diagnosis for a rare disease that no other doctor or clinic has been able to provide. Whole exome testing sequences more than 20,000 genes. That represents about one percent of a patient’s DNA — the part that we today understand contains the majority of useful genetic information that can pinpoint an illness. Patients can get their DNA mapped and have results within a few weeks to apply to their treatment plans. Prenatal screening could be made less invasive and more comfortable for patients with DNA sequencing, so we did that too. What we found was that DNA sequencing greatly expanded our ability to help patients by providing them with more informed and often more effective health care.

Treatment of cancers

One area where we’ve found DNA sequencing to be particularly effective is in the treatment of cancers.* One example that comes to mind is that of a young girl who had acute lymphoblastic leukemia, an aggressive form of blood cancer. None of the mainline therapeutic strategies had worked for this patient. But thankfully, DNA sequencing identified mutations in the cancer that could be leveraged. It’s clear from this example — and from many more like it — that DNA sequencing is a valuable tool in designing personalized treatments for some cancer patients. But there’s also benefit in potentially preventing the development of cancer in the first place. It’s estimated that between 10-15% of cancers involve a heritable mutation.* Current screening methods used to identify people who are at risk of developing cancer may miss up to 50% of heritable cancers. That leaves a lot of room for improvement, and DNA sequencing is proving to be a valuable tool in this regard.

Prevention of adverse drug reactions

Another valuable application is in the prevention of adverse drug reactions. It’s probably no surprise to learn that some people respond to medicine differently compared to others. In some of these cases, people may even have an unwanted or dangerous response to the drug. These are known as adverse drug reactions, and it’s estimated that approximately 1.5 million of them happen each year in the U.S., resulting in a thousand deaths annually. Research has shown us that some people are genetically predisposed to experiencing an adverse drug reaction, which means there’s an opportunity for DNA sequencing to help identify those individuals and help guide their treatment away from unnecessary risks.

My personal experience

It so happens that I’m one of those individuals. Through DNA sequencing, I found that I should avoid a number of medicines. Most of them are drugs that I will probably never need, but some of them I might. Thanks to this testing, I know what those are and can act accordingly in the future. This brings me to a benefit of DNA sequencing that I think we often overlook. I had my DNA sequenced and got information about my carrier status, potential drug reactions, and a number of health conditions. This was important to me because I have family members whose lives have been affected by a heritable genetic condition. I’ve found that having my DNA sequenced empowers me with knowledge — knowledge that I can use in the future to help guide medical treatment away from potentially dangerous drugs, and maybe even help my health care providers save valuable time if they’re ever looking for a diagnosis. So it’s not just a result that helps me stay informed today; it’s something I will likely use for the rest of my life. To be sure, DNA sequencing is not without its limitations.* When we first started in 2012, we were limited by the cost of sequencing and the time it took to receive and interpret a patient’s results. There is still so much we don’t know about genetics, and research is ongoing to determine how DNA sequencing is best applied. But this research has unlocked new avenues for improving outcomes in recent years, and I strongly believe this trend will continue. In the midst of this DNA sequencing revolution, I’ve had the unique opportunity to explore the field as a researcher, a physician, and an administrator, and I can tell you what an exciting time this is to be learning more about your genetics. My experience has shown me that DNA sequencing is not just a thing of the future — it’s a very real and impactful tool of the present.

Keith Stewart, M.B., CH.B., is the Carlson and Nelson Endowed Director of the Mayo Clinic Center for Individualized Medicine.

1. Manolio, Teri A. et al. “Implementing Genomic Medicine in the Clinic: The Future Is Here.” Genetics in Medicine 15.4 (2013): 258–267. PMC. Web. 21 Sept. 2018.   6. https://www.cancer.gov/about-cancer/causes-prevention/genetics

2. Delaney, Susan K. et al. “Toward Clinical Genomics in Everyday Medicine: Perspectives and Recommendations.” Expert Review of Molecular Diagnostics 16.5 (2016): 521–532. PMC. Web. 21 Sept. 2018.

3. Bryce, Alan H., et al. “Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib.” Clinical Genitourinary Cancer, vol. 15, no. 4, 2017, doi:10.1016/j.clgc.2016.11.001.

4. Torkamani, Ali et al. “High Definition Medicine.” Cell 170.5 (2017): 828–843. PMC. Web. 21 Sept. 2018.

5. Borad, Mitesh J. et al. “Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers.” Scientific Reports 6 (2016): 25. PMC. Web. 21 Sept. 2018.

6. https://www.cancer.gov/about-cancer/causes-prevention/genetics

The post Editorial: Why DNA sequencing is an effective tool for patient care appeared first on Mayo Clinic News Network.

ROCHESTER, Minn. — Mayo Clinic released a new DNA product with Helix, a personal genomics company, called "Mayo Clinic GeneGuide." The DNA-powered product provides healthy individuals with genetic testing and insights with a focus on education. This product is backed by Mayo medical science and expertise.

“The Mayo Clinic GeneGuide app uses the highest quality data to provide individuals with personal genomic insights, backed up with world class educational material helping users to understand their results and learn the language of genetics,” says Matthew Ferber, Ph.D., a Mayo Clinic genomics researcher who led the development of the app.

Watch:  Dr. Matthew Ferber

When an individual orders Mayo Clinic GeneGuide, the process begins with a Mayo-affiliated physician reviewing the individual’s health history. If Mayo Clinic GeneGuide is appropriate for the individual, the physician orders the test through Helix’s clinical lab that is accredited by the College of American Pathologists. Then Helix will ship a saliva collection kit to the individual within two days.

Once Helix receives the saliva sample at its accredited lab, the DNA is sequenced, resulting in 100 times more data than other types of genetic testing. These data are stored securely for future use. Then the genetic insights are interpreted by Mayo Clinic and the results are accessible on the Mayo Clinic GeneGuide web application.

Users receive genetic test reports that educate on health and disease risk. Health and disease risks range from complex illnesses and hereditary genetic conditions to how the body processes certain over-the-counter medications and physician-prescribed anesthesia. Decision-making tools help people better understand potential risks for specific health conditions. Individuals also can share their results with their health care provider for informed decision-making on actions related to their health.

"Mayo Clinic GeneGuide is an important step forward in helping people make informed health decisions involving DNA, and is a critical health product on the Helix platform," says Justin Kao, senior vice president and co-founder at Helix. “People are highly motivated to learn about how their DNA impacts their health. We harness the power of DNA sequencing, which allows us to offer health products that give more accurate risk indications. By partnering with Mayo Clinic on this product we are excited to advance our mission to empower every person to improve their lives through DNA.”

Mayo Clinic GeneGuide features include:

• Analysis of disease-causing genes for specific mutations associated with common hereditary conditions
• Educational modules written by Mayo Clinic experts who teach users about genetics and the specific conditions tested for by Mayo Clinic GeneGuide
• Additional content added over time powered by Helix’s Exome+ platform and available to users without requiring a new sample
• Secure and protected database
• Express consent which gives control to the user over how his or her genetic data is used and shared with any third party
• Access to Mayo Clinic-affiliated health care providers and their knowledge base, including genetic counselors
• Powered by Helix’s Exome+ DNA sequencing, which reads and securely stores 100 times more data than other tests, enabling users to access additional products and services from the Helix store without providing another saliva sample

“We need to work toward a future where everyone can benefit from individualized medicine products and services. Mayo Clinic GeneGuide will introduce genomics to a broader audience that Mayo Clinic aspires to engage and educate,” says Keith Stewart, M.B., CH.B., Carlson and Nelson Endowed Director of the Mayo Clinic Center for Individualized Medicine. “This is part of the future of medicine in which we routinely employ genomics and empower individuals to help predict and prevent disease.”

Dr. Ferber is available for interviews upon request.

Disclosure: Mayo Clinic has a financial interest in Helix.

Mayo Clinic GeneGuide is not available in Md., N.Y., N.J., R.I., and Pa.

Visit the Mayo Clinic GeneGuide website or the Helix product description page.

###

About Helix
Helix is a personal genomics company with a simple but powerful mission: to empower every person to improve his or her life through DNA. Helix has created the first marketplace for DNA-powered products where people can explore diverse and uniquely personalized products developed by high-quality partners. Helix handles sample collection, DNA sequencing and secure data storage so that its partners can integrate DNA insights into products across a range of categories, including ancestry, health, wellness and entertainment. From profound insights to just-for-fun discoveries, Helix is here to help people live a fuller life. Helix is headquartered in the San Francisco Bay Area, has an office in Denver, and operates a next-generation sequencing lab in San Diego that is accredited by Clinical Laboratory Improvement Amendments and College of American Pathologists, and powered by Illumina (Nasdaq:ILMN) NGS technology. Helix was created in 2015 with founding support from Illumina Inc., its largest shareholder. Learn more on the Helix website.

About Mayo Clinic Center for Individualized Medicine
The Mayo Clinic Center for Individualized Medicine discovers and integrates the latest in genomic, molecular and clinical sciences into personalized care for each Mayo Clinic patient. For more information, visit the Center for Individualized Medicine website.

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, providing expert, comprehensive care to everyone who needs healing. Learn more about Mayo Clinic. Visit the Mayo Clinic News Network.

Media contacts:

• Colette Gallagher, Mayo Clinic Public Affairs, 507-284-5005, newsbureau@mayo.edu
• Susan Buckles, Mayo Clinic Public Affairs, 507-284-5005, newsbureau@mayo.edu
• Helix, 415-692-6799, press@helix.com

The post New Mayo Clinic GeneGuide DNA testing application provides genetic testing, insights backed by Mayo Clinic expertise appeared first on Mayo Clinic News Network.

ROCHESTER, Minn. — Individualized medicine is tapping the human genome in new ways to attack health care disorders, predict risk of disease, make an earlier diagnosis and identify precise therapies. Individualized medicine, also called precision medicine, uses people's information about their genetic blueprints, lifestyles and environments to shape health care.

On Wednesday, Sept. 12, Keith Stewart, M.B., Ch.B., Carlson and Nelson Endowed Director, Mayo Clinic Center for Individualized Medicine, presented six ways precision medicine has further advanced into patient care over the past year. Dr. Stewart shared these innovations today in his opening welcome to the 2018 "Individualizing Medicine Conference: Advancing Care Through Genomics" in Rochester.

“In the 15 years since the first human genome was mapped, hundreds of thousands of patients have had their DNA sequenced, which has helped pinpoint the cause of disease and respond with individualized treatment,” says Dr. Stewart. “Fifteen years is a very short time in the history of medicine, and there’s still a lot we don’t know. Our research is helping us understand this emerging area of health care and its application to clinical practice. This conference is a great platform for sharing those discoveries.”

Dr. Stewart points to six key ways individualized medicine has advanced patient care over the past year:

1. Genomic testing is moving beyond disease to benefit healthy patients.
The cost of genomic sequencing has dropped sharply, making it possible to consider making DNA sequencing more widely available as a regular, pre-emptive clinical test for most patients. Mayo Clinic is conducting research to learn whether genetic testing of healthy patients might be as useful as a cholesterol test or regular cancer screening.

“We are interested in learning how we can use these tests to predict disease risk and intervene earlier. Further, we are exploring how genetic test results can be entered into the electronic health record in meaningful ways and studying how to improve care without increasing cost,” says Dr. Stewart.

2. Genetic testing is uncovering more hereditary links to cancer.
Research is finding that genetic testing is ushering in a new era of cancer prevention and treatment. DNA tests are identifying inherited genetic mutations ─ even in patients without a strong family history of cancer. A finding of hereditary cancer can influence cancer treatment and alert family members that they, too, should be screened to learn their risk for cancer. Investigators and physicians at Mayo Clinic are recommending expanding genetic testing as a cancer screening tool for all or nearly all cancer patients.

3. Research is advancing DNA blood tests to find and track the course of cancer.
Mayo Clinic has made great strides in developing DNA blood tests, known as liquid biopsies, that can detect the presence of cancer, monitor response to treatment and track recurrence before a tumor appears or returns. The test searches for DNA from cancer cells circulating in the bloodstream. Such blood tests may offer alternatives to X-rays and tissue biopsies, and may have the power to find cancer at an early stage when it is most curable.

 4. Genetically engineered cells that act as living drugs are a new option in cancer care.
Chimeric antigen receptor T-cell (CAR T-cell) therapy seeks to harness the power of each patient’s individual immune system by genetically modifying cells, equipping them with power to kill cancer. These engineered cells multiply and act like a living drug that uses the body’s defense system to fight disease.

 5. Artificial intelligence, also known as augmented human intelligence, is being tapped for individualized diagnosis and treatments.
Artificial intelligence, or augmented human intelligence, combines physician know-how with deep computer analysis to recognize patterns and trends that could lead to an early diagnosis. Machine learning could help radiologists by automatically processing thousands of images generated during an exam and identifying which images may be related to health and disease. Mayo Clinic also is studying ways augmented human intelligence can identify individualized therapies for breast cancer, depression and Alzheimer’s disease.

6. Drug-gene testing is more widely available.
Pharmacogenomics is the area of precision medicine that examines how a person’s genetic makeup influences how the body processes and responds to medications. Mayo Clinic is pre-emptively entering pharmacogenomics test results of more than 11,000 patients into the electronic health record to study how having this information could guide prescribers to safer and more effective medications. This is another step toward making pharmacogenomics testing available for more patients and health conditions.

Dr. Stewart is the Vasek and Anna Maria Polak Professor of Cancer Research Division of Hematology-Oncology, Mayo Clinic.

###

About Center for Individualized Medicine
Mayo Clinic Center for Individualized Medicine discovers, translates and applies new findings in genomic research into individualized medicine products and services for patients everywhere. Learn more on the Mayo Clinic Center for Individualized Medicine website.

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, providing expert, comprehensive care to everyone who needs healing. Learn more about Mayo Clinic. Visit the Mayo Clinic News Network.

Media Contact:

• Susan Buckles, Mayo Clinic Public Affairs, 507-284-5005, newsbureau@mayo.edu

The post 6 ways individualized medicine is advancing patient care appeared first on Mayo Clinic News Network.

ROCHESTER, Minn. — Experts in individualized medicine — the concept of shaping health care based on lifestyle, environment and genetic code — will be in Rochester Sept. 12-13 to present how the newest discoveries can be applied to personalized health care. These experts will be available for interviews at Individualizing Medicine 2018: Advancing Care Through Genomics, which will be held at Mayo Civic Center. The Individualizing Medicine Conference is sponsored by the Mayo Clinic Center for Individualized Medicine.

Members of the media are invited to interview experts on these topics:

• How the New Genomic Era of Medicine is Advancing Options for Individualized Care
  In the 15 years since the first human genome was mapped, the cost of sequencing your entire DNA has plummeted to just a few hundred dollars. Instead of taking years, DNA sequencing can be performed in weeks or days. DNA testing now plays an important role in the diagnosis and treatment of a wide range of health care conditions — even those who are healthy.Experts who can discuss how genomic medicine may influence future health care are Eric Green, M.D., Ph.D., director, National Human Genome Research Institute, and Keith Stewart, M.B., Ch.B., Carlson and Nelson endowed director, Mayo Clinic Center for Individualized Medicine.
• Your Best Defense Against Cancer May Be Found Within Your Individual Genetic Blueprint
  Research on a molecular level is unlocking new understanding of the power of the human body in the fight against cancer. Treatments, like chimeric antigen receptor (CAR) T-cell therapy, seek to unleash the immune system to search and destroy cancer. Advanced DNA testing panels may reveal whether a tumor is linked to a genetic mutation a person was born with. The results may affect treatment and take the guesswork out of who else in your family is at increased risk for cancer.Experts available for interview are Yi Lin, M.D., Ph.D., oncologist, Mayo Clinic Cancer Center (CAR T-cell Therapy); Michael Berger, Ph.D., geneticist, Memorial Sloan Kettering Cancer Center (advanced genomic testing); Kevin Halling, M.D., Ph.D., consultant, Mayo Clinic Department of Laboratory Medicine and Pathology (hereditary cancer); Heidi Nelson, M.D., director, Mayo Clinic Center for Individualized Medicine Microbiome program (microbiome role in cancer).
  
• Gene Editing: Ethical and Health Care Considerations
  Could a tool that acts as a ‘molecular scissor’ slice and remove diseased DNA? Or would some try to manipulate human embryos to create super babies with outstanding intelligence, talent and beauty? Intriguing as gene editing may sound; there are many ethical and health care implications to consider. Megan Allyse, Ph.D., bioethicist, Mayo Clinic Center for Individualized Medicine, can discuss the advantages and limitations.
• Artificial Intelligence – Will a Machine Decide Your Health Care?
  Research at Mayo Clinic is probing whether artificial intelligence can reduce the trial and error in prescribing medications such as antidepressants. Also known as augmented human intelligence, artificial intelligence combines deep computer analysis with human know-how to crack complex health conditions.
  Experts available for interview are Liewei Wang, M.D., Ph.D., Mayo Clinic Center for Individualized Medicine; Craig Mermel, M.D., Ph.D., Google Artificial Intelligence; Gabriel Krestin, M.D., Ph.D., machine learning and imaging, University Medical Center, Rotterdam, Netherlands; and Manolis Kellis, Ph.D., epigenomic applications of artificial intelligence, Massachusetts Institute of Technology Broad Institute.
• Pharmacogenomics: Medications Matched to Your Genetic Blueprint 
  One size does not fit all when it comes to medication. Research is uncovering ways health care providers can tap genetic blueprints to make decisions on individualized therapies for conditions ranging from cancer to depression. A standard drug that works for most patients might not work as intended for a patient. Or it could cause painful, life-threatening side effects.Experts who can talk about the importance of pre-emptive pharmacogenomics testing are Richard Weinshilboum, M.D., co-director, Pharmacogenomics Program, Mayo Clinic Center for Individualized Medicine; Imad Absah, M.D., pediatric gastroenterologist, Mayo Clinic; Teresa Kruisselbrink, supervisor and genetic counselor, Mayo Clinic Center for Individualized Medicine; and Timothy Curry, M.D., Ph.D., Education Program, Mayo Clinic Center for Individualized Medicine Education.

Dr. Stewart is the Vasek and Anna Maria Polak Professor of Cancer Research. Dr. Weinshilboum is the Mary Lou and John H. Dasburg Professor of Cancer Genomics, professor of medicine and pharmacology, at the Mayo College of Medicine and Science, and the Pharmacogenomics program director at the Mayo Clinic Center for Individualized Medicine.

###

About Center for Individualized Medicine
Mayo Clinic Center for Individualized Medicine discovers, translates and applies new findings in genomic research into individualized medicine products and services for patients everywhere. Learn more on the Mayo Clinic Center for Individualized Medicine website.

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, providing expert, comprehensive care to everyone who needs healing. Learn more about Mayo Clinic. Visit the Mayo Clinic News Network.

Media Contact:

• Susan Buckles, Mayo Clinic Public Affairs, 507-284-5005, newsbureau@mayo.edu

The post What’s next in precision medicine: Moving new discoveries into daily clinical care appeared first on Mayo Clinic News Network.

On the Mayo Clinic Radio podcast, Dr. Keith Stewart, Carlson and Nelson Endowed Director of the Mayo Clinic Center for Individualized Medicine, discusses the latest individualized cancer treatments, including liquid biopsy, biomarkers, and chimeric antigen receptor T-cell therapy. Dr. Stewart also previews the upcoming Individualizing Medicine 2018 conference. Also on the podcast, Dr. Kathryn Ruddy, director of cancer survivorship at the Mayo Clinic Cancer Center in Rochester, Minnesota, shares results of a study that found that many breast cancer survivors aren't following mammogram screening guidelines. And Dr. Christopher Russi, director of Community Emergency Medicine at Mayo Clinic, explains a pilot program that is using telemedicine during emergency transport.

The post #MayoClinicRadio podcast: 8/11/18 appeared first on Mayo Clinic News Network.

On the next Mayo Clinic Radio program, Dr. Keith Stewart, Carlson and Nelson Endowed Director of the Mayo Clinic Center for Individualized Medicine, will discuss the latest individualized cancer treatments and preview the upcoming Individualizing Medicine 2018 conference. Also on the program, Dr. Kathryn Ruddy, director of cancer survivorship at the Mayo Clinic Cancer Center in Rochester, Minnesota, will share results of a study that found that many breast cancer survivors aren't following mammogram screening guidelines. And Dr. Christopher Russi, director of Community Emergency Medicine at Mayo Clinic, will explain a pilot program that is using telemedicine during emergency transport.

To hear the program, find an affiliate in your area.

Use the hashtag #MayoClinicRadio, and tweet your questions.

Mayo Clinic Radio is on iHeartRadio.

Access archived shows or subscribe to the podcast.

Mayo Clinic Radio produces a weekly one-hour radio program highlighting health and medical information from Mayo Clinic.

The post Mayo Clinic Radio: Individualizing Medicine 2018 conference appeared first on Mayo Clinic News Network.

On the next Mayo Clinic Radio program, Dr. Keith Stewart, Carlson and Nelson Endowed Director of the Mayo Clinic Center for Individualized Medicine, will discuss the latest individualized cancer treatments and preview the upcoming Individualizing Medicine 2018 conference. Also on the program, Dr. Kathryn Ruddy, director of cancer survivorship at the Mayo Clinic Cancer Center in Rochester, Minnesota, will share results of a study that found that many breast cancer survivors aren't following mammogram screening guidelines. And Dr. Christopher Russi, director of Community Emergency Medicine at Mayo Clinic, will explain a pilot program that is using telemedicine during emergency transport.

To hear the program, find an affiliate in your area.

Miss the show?  Here's your Mayo Clinic Radio podcast.

Use the hashtag #MayoClinicRadio, and tweet your questions.

Mayo Clinic Radio is on iHeartRadio.

Access archived shows or subscribe to the podcast.

Mayo Clinic Radio produces a weekly one-hour radio program highlighting health and medical information from Mayo Clinic.

The post Mayo Clinic Radio: Individualized medicine / breast cancer survivors and mammograms / telemedicine during emergency transport appeared first on Mayo Clinic News Network.